S&P Midcap 400 Divd Proshares (REGL)
$56.59 0.35 (0.61%)
18:30 EDT REGL Stock Quote Delayed 30 Minutes
Previous Close $56.59
Market Cap 437.16M
PE Ratio -
Volume (Avg. Vol.) 51,731
Day's Range 56.38 - 56.89
52-Week Range 37.74 - 61.37
Dividend & Yield 1.08 (1.91%)
REGL Stock Predictions, Articles, and S&P Midcap 400 Divd Proshares News
- From InvestorPlace
- From the Web
With S&P 500 dividends under duress this year, investors should focus on quality dividend aristocrat ETFs that offer impressive growth.
With all the cheap ETFs on the market, investors often think that the cheapest funds are the best ETFs to buy. But these ETFs earn their fees.
Several ETFs track indices known as 'dividend aristocrats' indices. These funds emphasize dividend growth, not yield, and they're not perfect ...
Retirement stocks can often be limited with 401k investing, but when investing for retirement, dividend aristocrat funds can provide a healthy combination of income and growth.
From Smarter Analyst
From Seeking Alpha
After William Blair and JMP Securities gave Ovid Therapeutics (NASDAQ: OVID) a Buy rating last month, the company received another Buy, this time from Ladenburg Thalmann & Co. Analyst Michael Higgins maintained a Buy rating on Ovid Therapeutics today and set a price target of $21.00. The company’s shares closed last Wednesday at $7.07. According
In a report issued on July 13, Tim Lugo from William Blair maintained a Buy rating on Ovid Therapeutics (OVID – Research Report). The company’s shares closed last Friday at $7.20. According to TipRanks.com, Lugo is a 5-star analyst with an average return of 16.0% and a 50.2% success rate. Lugo covers the Healthcare sector,
Ladenburg Thalmann & Co. analyst Michael Higgins reiterated a Buy rating on Ovid Therapeutics (OVID – Research Report) today and set a price target of $21.00. The company’s shares closed last Monday at $7.79. According to TipRanks.com, Higgins has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -6.1%